Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients

Autor: Jørn Herrstedt, Gunnar B. Kristensen, Andreas du Bois, Eric Pujade Lauraine, Edibe Erol, R. Richter, Christina Fotopoulou, Jacobus Pfisterer, Alexander Reuss, Jalid Sehouli, Sven Mahner

Publikováno v: Sehouli, J, Fotopoulou, C, Erol, E, Richter, R, Reuss, A, Mahner, S, Lauraine, E, Kristensen, G, Herrstedt, J, du Bois, A & Pfisterer, J 2015, ' Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients ', European Journal of Cancer, vol. 51, no. 7, pp. 825-832 . https://doi.org/10.1016/j.ejca.2015.01.008

Purpose Alopecia is a common side-effect of chemotherapy and affects quality of life of cancer patients. Some patients and physicians believe that alopecia could be a surrogate marker for response to chemotherapy and impact on prognosis. However, thi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c04b2eaef069722618c49430e824c9e
https://portal.findresearcher.sdu.dk/da/publications/ae9c23dc-3be3-4609-89f5-c427cbf14f0b

Haaruitval door gebruik van geneesmiddelen

Publikováno v: Nederlands Tijdschrift voor Geneeskunde. 143(19):990-4

Hairs are produced in hair follicles that have a cyclic activity. The cycles that normal hair follicles go through are the metabolically active anagen phase, the catagen transitional phase and the resting telogen phase. Loss of more than 120 hairs da

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dris___00893::d3852d457c4a8f07f39ef790ae8c083b
https://www.ntvg.nl/artikelen/haaruitval-door-gebruik-van-geneesmiddelen/volledig

Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP

Autor: Economopoulos, T., Dimopoulos, M. A., Mellou, S., Pavlidis, N., Samantas, E., Nicolaides, C., Tsatalas, C., Papadopoulos, A., Papageogriou, E., Papasavvas, P., Fountzilas, G.

INTRODUCTION: During the last few years epirubicin (E) and mitoxantrone (M) (Novantrone) have been used in the treatment of non-Hodgkin's lymphoma (NHL), because of their favorable principal profile. In particular, M has less severe non-hematological

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10561::39a0c4b92b9223774136382fea3be2c1
http://olympias.lib.uoi.gr/jspui/handle/123456789/20343

Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer

Autor: Fountzilas, G., Athanassiades, A., Kalogera-Fountzila, A., Samantas, E., Bacoyiannis, C., Briassoulis, E., Pavlidis, N., Kosmidis, P., Skarlos, D.

We performed a phase II study to evaluate the activity and toxicity of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin as first-line treatment in patients with recurrent or metastatic head and neck c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10561::5a2850cf5ae943dbb1d39aadb464380d
http://olympias.lib.uoi.gr/jspui/handle/123456789/19486

Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors

Autor: Hans Gelderblom, Salazar R, Verweij J, Pentheroudakis G, Mj, Jonge, Devlin M, van Hooije C, Seguy F, Obach R, Pruñonosa J, Principe P, Twelves C

Publikováno v: Europe PubMed Central
Clinical Cancer Research, 9, 4101-4107. American Association for Cancer Research Inc.

PURPOSE: Diflomotecan (BN80915) is an E-ring modified camptothecin analogue that possesses greater lactone stability in plasma compared with other topoisomerase I inhibitors, a potential advantage for antitumor activity. As with other camptothecins,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::509f969795fe2c3edbfab81daf909c39
http://europepmc.org/abstract/med/14519632